Cargando…

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease without any approved treatment to-date despite intensive research efforts by researchers and pharmaceutical industry. Fibroblast growth factor (FGF)-21 has been gaining increasing attention as a possible contributing factor and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raptis, Dimitrios D, Mantzoros, Christos S, Polyzos, Stergios A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879042/ https://www.ncbi.nlm.nih.gov/pubmed/36713291 http://dx.doi.org/10.2147/TCRM.S352008

Ejemplares similares

Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)
por: Polyzos, Stergios A., et al.
Publicado: (2020)

Combination Therapies for Nonalcoholic Fatty Liver Disease
por: Makri, Evangelia S., et al.
Publicado: (2022)

Innate immunity and nonalcoholic fatty liver disease
por: Kountouras, Jannis, et al.
Publicado: (2023)

The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
por: Vachliotis, Ilias D., et al.
Publicado: (2023)

Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma
por: Vachliotis, Ilias D., et al.
Publicado: (2023)

Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease
por: Boutari, Chrysoula, et al.
Publicado: (2018)

Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease
por: Alisi, Anna, et al.
Publicado: (2013)

Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
por: Tian, Haoyu, et al.
Publicado: (2023)

Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
por: Wu, Guangyu, et al.
Publicado: (2017)

Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events
por: Wu, Liang, et al.
Publicado: (2020)

Retinal Vascular Lesions in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Orfanidou, Myrsini, et al.
Publicado: (2023)

Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
por: Vachliotis, Ilias D., et al.
Publicado: (2023)

SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease
por: Colak, Yasar, et al.
Publicado: (2011)

Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease
por: Lin, Chuan-Hao, et al.
Publicado: (2018)

Thrombospondin1 as a potential therapeutic target for human nonalcoholic fatty liver disease
por: Song, Yongfeng, et al.
Publicado: (2020)

Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

The anti-inflammatory potential of diet and nonalcoholic fatty liver disease: the ATTICA study
por: Tyrovolas, Stefanos, et al.
Publicado: (2019)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
por: Valenzuela-Vallejo, Laura, et al.
Publicado: (2023)

Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases
por: Sousa-Lima, Inês, et al.
Publicado: (2021)

Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs
por: Huang, Xiaojing, et al.
Publicado: (2023)

Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease
por: Dibba, Pratima, et al.
Publicado: (2018)

Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
por: Li, Xinyue, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
por: Sotiropoulou, Maria, et al.
Publicado: (2021)

Growth hormone and nonalcoholic fatty liver disease
por: Ma, Ingrid L., et al.
Publicado: (2023)

Focus on Therapeutic Strategies of Nonalcoholic Fatty Liver Disease
por: Durazzo, Marilena, et al.
Publicado: (2012)

Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice
por: Zhao, Cuiqing, et al.
Publicado: (2019)

Metabolic Targets in Nonalcoholic Fatty Liver Disease
por: Esler, William P., et al.
Publicado: (2019)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021)

New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans
por: Inzaugarat, María Eugenia, et al.
Publicado: (2017)

mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease
por: Feng, Jiayao, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies
por: Huang, Yue Ye, et al.
Publicado: (2013)

Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications
por: Andronescu, Craita Isabela, et al.
Publicado: (2018)

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
por: Yu, Yao, et al.
Publicado: (2018)

Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease
por: Mijangos-Trejo, Alejandra, et al.
Publicado: (2023)

The lipidome in nonalcoholic fatty liver disease: actionable targets
por: Pirola, Carlos J., et al.
Publicado: (2021)

Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2023)

Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass
por: Guo, Jiun-Yu, et al.
Publicado: (2022)

An Open-Label Exploratory Clinical Trial Evaluating the Effects of GLS (Coptidis Rhizoma-Evodiae Fructus 2 : 1) on Fibroblast Growth Factor 21 in Patients with Nonalcoholic Fatty Liver Disease
por: Zhang, Yang, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4hdvp0rpnqijeotu3h3f3aoktj